Dr. Kiran Turaga
Director of Gastrointestinal Cancer Surgery at University of Chicago Medicine
Dr. Kiran Turaga is a cytoreduction and HIPEC specialist at University of Chicago Medicine’s Comprehensive Cancer Center. He sees patients with peritoneal surface malignancies, which includes peritoneal mesothelioma.
University of Chicago Comprehensive Cancer Center
5841 S. Maryland Avenue, Chicago, IL 60637
JUMP TO A TOPIC
More About Mesothelioma Specialist Dr. Kiran Turaga
Dr. Turaga is a lead cytoreduction surgeon and HIPEC specialist at University of Chicago Medicine. He sees patients out of the affiliated cancer center in the metropolis.
Dr. Turaga is one of many peritoneal mesothelioma surgeons to receive training at University of Pittsburgh Medical Center. This hospital is considered the first high-volume center for peritoneal mesothelioma. Many current mesothelioma surgeons completed fellowships at UPMC.
Dr. Turaga’s titles at University of Chicago Medicine include:
- Vice Chief for the Section of General Surgery and Surgical Oncology
- Director of the Surgical Gastrointestinal Cancer Program
- Director of the Regional Therapeutics Program
He’s also a professor of surgery at University of Chicago. He also taught at the Medical College of Wisconsin and Moffitt Cancer Center in Tampa, Florida. He is fellowship director for the Complex General Surgical Oncology Fellowship program at University of Chicago Medicine.
- Medical Degree from All India Institutes of Medical Sciences, 2001
- Master’s Degree in Public Health from Johns Hopkins University in Baltimore, Maryland, 2003
- Residency at Creighton University Medical Center in Omaha, Nebraska
- Fellowship at H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida
- Fellowship at University of Pittsburgh Medical Center
- Received the Department of Surgery Excellence in Teaching award, 2017
Get Connected to Dr. Kiran Turaga
Dr. Kiran Turaga is a HIPEC expert at University of Chicago Medicine. He trained at University of Pittsburgh Medical Center and completed two fellowships, one at Moffitt Cancer Center. He’s a trusted surgeon for peritoneal mesothelioma.
Why Choose Dr. Turaga?
- Director of gastrointestinal cancer surgery at a top cancer hospital
- Clinical interest in helping patients live past usual prognosis
- Co-authored medical articles on peritoneal mesothelioma
Expertise With HIPEC for Mesothelioma
Dr. Turaga’s clinical interest includes perfecting HIPEC and surgery for peritoneal surface malignancies. This therapy is widely viewed as the best option to improve life expectancy for cases of peritoneal mesothelioma.
HIPEC is a regional treatment delivering high doses of heated chemotherapy to the abdominal cavity. The therapy, officially called “hyperthermic intraperitoneal chemotherapy”, kills cancer cells that persist in the abdomen after surgical removal of the:
- Affected organs and tissue
Participation in Important Research
Dr. Turaga’s research is featured in more than 100 peer-reviewed medical articles. Just in the last few years, he has collaborated with fellow mesothelioma specialists on multiple articles about this rare asbestos cancer.
In 2021, he worked with University of Chicago Medicine colleague Dr. Hedy Lee Kindler on learning how much PD-L1 protein expression occurs in malignant peritoneal mesothelioma. He found the expression was higher in cases with specific cell mutation and lower in cases with prior chemotherapy.
In 2014, he reviewed survival after cytoreduction and HIPEC surgery. More than half of patients achieved three-year survival, and around 40% reached five years.
Dr. Turaga found the survival improved slightly when patients received early postoperative intraperitoneal chemotherapy (EPIC) through the ports used during HIPEC. This therapy sends cancer-killing drugs back into the abdominal cavity a few weeks after surgery to continue bathing the area with chemotherapy drugs that are harmful to lingering cancer cells.
Immunotherapy Drugs for Peritoneal Mesothelioma
Dr. Turaga is leading a new study investigating two immune checkpoint inhibitors for peritoneal mesothelioma. The therapies, Opdivo and Yervoy, are approved by the FDA for unresectable pleural mesothelioma.
Dr. Turaga’s study, which opens in 2022, uses Opdivo and Yervoy (brand names for nivolumab and ipilimumab, respectively) prior to surgery. The objective is to assess tumor response to the immunotherapy treatment and how many patients advance to surgery without delays.
How to Connect With Dr. Turaga
Dr. Turaga sees new patients through University of Chicago Medicine’s cancer center. He accepts cases of peritoneal mesothelioma from throughout the country. Despite the rarity of this disease, Dr. Turaga and his colleagues have a high case volume every year.
We can put you in touch with Dr. Turaga and the gastrointestinal surgery team at University of Chicago Medicine. Contact a patient advocate through the Mesothelioma Guide website or email Karen Ritter, our registered nurse, at email@example.com.
Sources & Author
- Kiran Turaga, MD, MPH. UChicago Medicine. Retrieved from: https://bucksbauminstitute.uchicago.edu/bio/kiran-turaga/. Accessed: 11/22/2021.
- Kiran K. Turaga, MD, MPH. UChicago Medicine. Retrieved from: https://www.uchicagomedicine.org/find-a-physician/physician/kiran-turaga. Accessed: 11/22/2021.
- Kiran Turaga. University of Chicago. Retrieved from: https://profiles.uchicago.edu/profiles/display/8615164. Accessed: 11/22/2021.
- Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis. Annals of Surgical Oncology. Retrieved from: https://pubmed.ncbi.nlm.nih.gov/25124472/. Accessed: 11/23/2021.
- Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy. British Journal of Cancer. Retrieved from: https://pubmed.ncbi.nlm.nih.gov/33100328/. Accessed: 11/23/2021.
- A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma. Clinicaltrials.gov. Retrieved from: https://clinicaltrials.gov/ct2/show/NCT05041062. Accessed: 12/01/2021.